A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

NCT07497386 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable Locally Recurrent Breast Cancer
Unresectable Locally Metastatic Breast Cancer

Interventions

DRUG: Trastuzumab Rezetecan for Injection
DRUG: Trastuzumab Deruxtecan for Injection

Sponsor

Jiangsu HengRui Medicine Co., Ltd.